CrownBio and Hubrecht Organoid Technology Announce a Strategic Partnership, including Exclusive License to Provide Oncology Organoid-Based Preclinical Drug Development and Validation Services
Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform
SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation and autoimmune, cardiovascular and metabolic disease research announced today that parent company, JSR Corporation, has entered into a strategic partnership with Hubrecht Organoid Technology (HUB).
The agreement provides CrownBio, a wholly owned subsidiary of JSR Corporation, with an exclusive license to provide preclinical oncology drug development and validation services using HUB Organoid Technology, including access to HUB’s highly characterized tumor organoid biobank. CrownBio and HUB will also launch a collaborative research & development program to accelerate further development of Organoid Technology, while CrownBio will establish a new operations center in Utrecht, Netherlands.
HUB’s adult stem cell-derived organoids, developed by Prof. Hans Clevers at the Hubrecht Institute in Utrecht, are generated using highly standardized, proprietary culture methods. The Organoids faithfully recapitulate tumors in patients and are extensively characterized by pathology, genomics, and sensitivity to known and experimental drugs.
“This agreement is a pivotal moment in our growth and the evolution of the company,” said Dr. Jean-Pierre Wery, CEO of CrownBio. “This partnership positions CrownBio at the forefront of global preclinical research by creating an unparalleled translational platform to accelerate drug development and validation.”
Building on a global leadership in Patient-Derived Xenografts (PDX), CrownBio will offer comprehensive pharmacology and translational services based on HUB Organoid Technology, establishing a unique platform that incorporates in vitro screening of Patient-Derived Organoids (PDO) and PDX derived organoids (PDXO), matched to downstream in vivo models.
“We are delighted with the increased access to HUB Organoid Technology for researchers worldwide through CrownBio’s global reach and preclinical service expertise,” said Dr. Robert Vries, Executive Director of HUB. “Our partnership with CrownBio equips the drug development community with powerful new translational tools to guide the creation of novel and improved treatments for cancer.”
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates. For more information about CrownBio’s translational oncology platforms visit https://www.crownbio.com
Hubrecht Organoid Technology (HUB) is an organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. HUB exploits the pioneering work of Prof. Hans Clevers, who discovered methods to grow stem cell-derived human ‘mini-organs’ (HUB Organoids) from tissues of patients with various diseases. The organoids, which are part of the HUB biobanks, are characterized by genome sequencing, expression profiling and sensitivity to known and experimental drugs to establish a database linking genetic and transcriptional information to drug responsiveness. HUB offers licenses to its patented HUB Organoid Technology and access to organoids from the HUB biobank for preclinical drug screening, discovery, development and validation. In addition, HUB is performing clinical studies to validate the technology’s use as a companion diagnostic. More info at www.hub4organoids.eu .
Crown Bioscience Inc.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Erytech Pharma S.A.24.6.2019 23:32:28 CEST | Pressemeddelelse
ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies
Vricon24.6.2019 14:32:47 CEST | Pressemeddelelse
U.S. Army awards Vricon contract for One World Terrain
Erytech Pharma S.A.24.6.2019 07:32:40 CEST | Pressemeddelelse
ERYTECH Announces Opening of Operations at its New Princeton, NJ GMP Manufacturing Facility
Wildflower Brands Inc.21.6.2019 14:32:20 CEST | Pressemeddelelse
Wildflower Featured in NetworkNewsWire Publication Summarizing Amazing Profits Found in Cannabis
ADC Therapeutics SA21.6.2019 07:02:09 CEST | Pressemeddelelse
ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
TriLumina20.6.2019 19:02:26 CEST | Pressemeddelelse
TriLumina Launches the World’s First Surface-Mount Flip-Chip Back-Emitting VCSEL Array Without the Need for a Submount
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum